Astellas receives positive chmp opinion for evrenzo™ (roxadustat) for adult patients with symptomatic anemia of chronic kidney disease

Tokyo, june 25, 2021 (globe newswire) -- astellas pharma inc. (tse: 4503, president and ceo: kenji yasukawa, ph.d., "astellas") and fibrogen, inc. (nasdaq: fgen, ceo: enrique conterno, "fibrogen") today announced the committee for medicinal products for human use (chmp) of the european medicines agency (ema) has adopted a positive opinion relating to the use of roxadustat for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (ckd).1 ckd impacts one in 10 people globally, of whom one in five are affected by anemia.2, 3 anemia of ckd is associated with significant impairment in quality of life and progression to adverse cardiovascular (cv) and renal outcomes.4-6 anemia of ckd is often untreated or not treated to target.4-6
FGEN Ratings Summary
FGEN Quant Ranking